AstraZeneca's experimental drug, camizestrant, significantly reduces the risk of breast cancer progression or death in ...

A large prospective, randomized clinical trial in patients with advanced breast cancer has found that the use of liquid ...

Vepdegestrant, an investigational estrogen receptor (ER) degrader, known as a proteolysis-targeting chimera (PROTAC ), ...

Camizestrant plus CDK4/6 inhibition improved progression-free survival when given to patients with ESR1-mutant ER+/HER2– ...

Data presented at ASCO show that swapping in the oral drug camizestrant for an older therapy helped sustain the benefit of ...

Approximately 70% of breast cancers are HR-positive/HER2 negative. While activating ESR1 mutations are rare at the time of ...

A clinical trial found that women could switch drugs without waiting for scans showing cancer progression, which improved ...

A dual-target CAR T cell therapy approach shows promise for slowing tumor growth in a notoriously aggressive and fast-growing ...

It's a condition that affects more than 10 million people in the UK. It can change futures, end careers, and shrink worlds.

Pivotal Phase 3 VERITAC-2 clinical trial results presented at ASCO demonstrate 2.9-month improvement in median progression-free survival when compared to fulvestrant in second line-plus patients with ...

While vepdegestrant outperformed a standard treatment option in a subtype of patients, the benefit on progression-free ...

A North Texas woman says a new medication treating postpartum depression helped her get through the hardest year of her life.